Thermo Fisher Beats Q3, Lifts 2026 EPS and Sales Guidance
TMO sits 60% above its 52-week low of $435.27.
Summary
Q3 adjusted EPS of $6.68 came in well above the $6.40 consensus, and sales of $12.14B beat the $11.95B estimate with 6% organic growth. The bigger item is guidance: management raised FY2026 adjusted EPS to $25.13-$25.43 from $24.93-$25.33 and sales to $47.70B-$48.20B from $47.4B-$48.10B. Adjusted operating margin expanded to 24.5% from 23.3%, so the beat is flowing through to profitability rather than being bought with spending. Segment mix was uneven — Laboratory Products and Biopharma Services grew 15% reported (10% organic) while Specialty Diagnostics fell 6% reported on flat organic revenue. CEO Marc Casper said pharma and biotech grew high-single digits and that the improved end-market conditions from Q2 carried into Q3, which is the demand read-through that matters for the 2027 setup. Shares were up about 1% at $694.55, near the 52-week high, so the market has already priced in much of the beat.
At the time of this announcement, TMO was trading at $696.57 on NYSE in the Life Sciences sector, with a market capitalization of approximately $257.6B. The 52-week trading range was $435.27 to $705.79. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.